Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing rademikibart, an antibody designed to target IL-4Rα for asthma and COPD. The company is headquartered in San Diego and has no commercial product revenue yet, relying on clinical progress, licensing, and collaboration economics to fund development.

−89 640,6 %

−86 687,5 %

−99,8 %

3.74

3.74

— Connect Biopharma Holdings Ltd
%
Lead biologic candidate0% Rademikibart is the company's core antibody program being advanced for asthma and COPD.
Clinical development services0% Internal R&D work covering discovery, preclinical studies, and clinical trials.
License and collaboration revenue100% Milestones and reimbursements from the Simcere partnership in Greater China.
Regulatory and IP activities0% Filing, prosecution, and maintenance of patents and marketing approvals.

Connect Biopharma does not sell a marketed drug directly to end customers today; its economic counterparties are...

  • Strategic license partnerprimary

    Simcere licenses rademikibart for Greater China and pays milestones, reimbursements, and future royalties.

  • Regulatory authoritiesprimary

    Health agencies review clinical, safety, and manufacturing data needed for approval and commercialization.

  • Asthma and COPD patientssecondary

    Future end users of rademikibart if the drug is approved and commercialized.

  • Physicians and hospitalssecondary

    Pulmonologists and treating clinicians would adopt the therapy based on efficacy and safety data.

  • Payers and health systemssecondary

    Insurers and health systems would influence uptake through reimbursement and formulary access.

The company is headquartered in San Diego, California, but its most explicit commercial exposure is Greater China...

  • •Headquartered in San Diego, California
  • •Greater China is the key licensed commercialization territory
  • •Simcere covers mainland China, Hong Kong, Macau, and Taiwan
  • •U.S. is the base for corporate and clinical operations
  • •China exposure matters because of regulatory and IP execution risk

The company’s strategy is to advance rademikibart through clinical development while using partnerships to extend reach...

01
Complete Phase 2 acute exacerbation studiesshort-term

Clinical readouts are the main value driver for a clinical-stage biotech with no product sales.

02
Advance regulatory progress in China through Simcereshort-term

China NDA progress can trigger milestones and future royalties while validating the asset.

03
Maintain cash runway and control development spendshort-term

The company is pre-commercial and depends on existing cash and external financing.

04
Strengthen intellectual property and collaboration structuremedium-term

Exclusive rights and patent protection are central to future partnering and commercialization value.

Connect Biopharma faces the typical risks of a clinical-stage biotech: trial failure, regulatory delays, and the...

critical

Clinical development failure

Rademikibart is still in development, so negative efficacy or safety data could eliminate the main value driver.

Scope
Phase 2 asthma and COPD programs
Materiality
high
high

Regulatory approval risk

Approval timing and outcomes depend on regulators in the U.S. and China, and delays can defer commercialization and milestones.

Scope
NDA review and future marketing approvals
Materiality
high
high

China partner execution risk

The company relies on Simcere to develop, manufacture, and commercialize rademikibart in Greater China.

Scope
Greater China license agreement
Materiality
high
high

Financing and dilution risk

The company is loss-making and expects to fund operations through equity, debt, or collaborations.

Scope
Future capital raises
Materiality
high
medium

Intellectual property and data-security risk

Biotech value depends on patent protection and secure handling of proprietary and patient data.

Scope
Patents, trade secrets, PRC and U.S. privacy/cyber rules
Materiality
medium
Revenue recognition for collaboration fees
Can cause large swings in quarterly revenue, as seen in the Simcere agreement
Accrued research and development expenses
Affects operating expense timing and reported losses
Share-based compensation
Raises reported R&D and G&A expense without immediate cash outflow
Fair value of short-term investments
Influences liquidity presentation and interest-related income

IMPACT BIOMEDICAL INC.

IBO · Pharmaceutical Preparations

Arbutus Biopharma Corp

ABUS · Pharmaceutical Preparations

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

Aspire Biopharma Holdings, Inc.

ASBP · Pharmaceutical Preparations

Cue Biopharma, Inc.

CUE · Pharmaceutical Preparations

Immix Biopharma, Inc.

IMMX · Pharmaceutical Preparations

: 28/04/2026